Status:
RECRUITING
Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia
Lead Sponsor:
National Cancer Center, Japan
Conditions:
Rare Malignant Neoplasm
Eligibility:
All Genders
18+ years
Brief Summary
This is a registry study that aims to collect patients' data with advanced-stage rare cancer in Asia-Pacific region. Data includes clinical information, details of treatment, prognosis, pathological d...
Eligibility Criteria
Inclusion
- Patients with a histological diagnosis of rare cancer, cancer of unknown primary origin, or cancer of rare tissue subtypes of common cancers. (Defined in protocol.)
- Patients with Advanced stage cancer.
Exclusion
- 1\. Patients with complications of cognitive impairment.
Key Trial Info
Start Date :
November 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2030
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05217407
Start Date
November 30 2021
End Date
March 31 2030
Last Update
March 22 2024
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Center Hospital, Japan
Chuo-ku, Tokyo, Japan, 104-0045
2
Hospital Sultan Ismail
Johor Bahru, Johor, Malaysia
3
Hospital Pulau Pinang
Pulau Pinang, Pulau Pinang, Malaysia
4
Sarawak General Hospital
Kuching, Sarawak, Malaysia, 93586